Perioperative antibiotic prophylaxis in renal transplantation: a single-center comparison between two regimens and a brief survey among the Eurotransplant renal transplantation centers.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
May 2019
Historique:
received: 17 05 2018
accepted: 07 08 2018
pubmed: 16 8 2018
medline: 18 12 2019
entrez: 16 8 2018
Statut: ppublish

Résumé

Perioperative antibiotic prophylaxis (PAP) is an integral part of kidney transplantation to prevent surgical site infections (SSI). In July 2015, we changed our standard from a multiple-dose to a single-dose (SD) prophylaxis. Here, we report on results with both regimens and a related survey among Eurotransplant renal transplantation centers. From July 2015, all kidney graft recipients of our center were scheduled to receive SD i.v. cefazolin (group SD, n = 107). They were compared to patients, transplanted since January 2014, receiving our previous standard (i.v. piperacillin/flucloxacillin) until postoperative day (POD) 7, plus oral sultamicillin until POD 10 (group MD, n = 105). The primary endpoint was the number of SSIs during a 3-month observational period. The frequency of SSI episodes was generally low (group SD vs. MD: 2 vs. 4, p = 0.40). Of note, urinary tract infections occurred in 40 SD vs. 36 MD patients, respectively (p = 0.60). Urinary tract infections were caused by Escherichia coli in 36.8%. Female gender was the only independent risk factor on multivariate analysis (p = 0.002). In addition, 12 episodes of urosepsis in both groups occurred. All-cause infection with multi-resistant bacteria occurred less frequently in SD vs. MD patients (3.7% vs. 8.6%, p = 0.16). A majority of Eurotransplant centers used i.v. single-dose cephalosporins (36.9%), although substances and duration varied remarkably. Single-dose cefazolin was equally effective and less expensive compared to our previous MD regimen. Based on these findings, we conclude that future prospective studies should be designed to confirm the non-inferiority of single-dose antibiotic regimens.

Sections du résumé

BACKGROUND BACKGROUND
Perioperative antibiotic prophylaxis (PAP) is an integral part of kidney transplantation to prevent surgical site infections (SSI). In July 2015, we changed our standard from a multiple-dose to a single-dose (SD) prophylaxis. Here, we report on results with both regimens and a related survey among Eurotransplant renal transplantation centers.
METHODS METHODS
From July 2015, all kidney graft recipients of our center were scheduled to receive SD i.v. cefazolin (group SD, n = 107). They were compared to patients, transplanted since January 2014, receiving our previous standard (i.v. piperacillin/flucloxacillin) until postoperative day (POD) 7, plus oral sultamicillin until POD 10 (group MD, n = 105). The primary endpoint was the number of SSIs during a 3-month observational period.
RESULTS RESULTS
The frequency of SSI episodes was generally low (group SD vs. MD: 2 vs. 4, p = 0.40). Of note, urinary tract infections occurred in 40 SD vs. 36 MD patients, respectively (p = 0.60). Urinary tract infections were caused by Escherichia coli in 36.8%. Female gender was the only independent risk factor on multivariate analysis (p = 0.002). In addition, 12 episodes of urosepsis in both groups occurred. All-cause infection with multi-resistant bacteria occurred less frequently in SD vs. MD patients (3.7% vs. 8.6%, p = 0.16). A majority of Eurotransplant centers used i.v. single-dose cephalosporins (36.9%), although substances and duration varied remarkably.
CONCLUSION CONCLUSIONS
Single-dose cefazolin was equally effective and less expensive compared to our previous MD regimen. Based on these findings, we conclude that future prospective studies should be designed to confirm the non-inferiority of single-dose antibiotic regimens.

Identifiants

pubmed: 30109484
doi: 10.1007/s00345-018-2440-2
pii: 10.1007/s00345-018-2440-2
doi:

Substances chimiques

Anti-Bacterial Agents 0
Floxacillin 43B2M34G2V
sultamicillin 65DT0ML581
Ampicillin 7C782967RD
Cefazolin IHS69L0Y4T
Sulbactam S4TF6I2330
Piperacillin X00B0D5O0E

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

957-967

Auteurs

Friederike Bachmann (F)

Department of Nephrology and Medical Intensive Care, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany. friederike.bachmann@charite.de.

Thomas Adam (T)

Department of Microbiology, Labor Berlin GmbH, Berlin, Germany.

Frank Friedersdorff (F)

Department of Urology, Charité University Medicine Berlin, Berlin, Germany.

Lutz Liefeldt (L)

Department of Nephrology and Medical Intensive Care, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Torsten Slowinski (T)

Department of Nephrology and Medical Intensive Care, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Klemens Budde (K)

Department of Nephrology and Medical Intensive Care, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Johannes Waiser (J)

Department of Nephrology and Medical Intensive Care, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH